ロード中...
The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma
High-dose interleukin-2 (HD IL-2) is an approved immunotherapy agent for metastatic melanoma and renal cell carcinoma resulting in objective responses in 15–20 % of patients. An additional subset of patients achieves stable disease, and the natural history of these patients has not been well documen...
保存先:
| 出版年: | Cancer Immunol Immunother |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4448124/ https://ncbi.nlm.nih.gov/pubmed/25603775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-014-1652-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|